Skip to Main Content

Author Details

Henry Rodriguez
Office of Cancer Clinical Proteomics Research, National Cancer Institute
1983
187
73
Emma Lundberg (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36470426Mapping the KRAS proteoform landscape in colorectal cancer identifies truncated KRAS4B that decreases MAPK signaling.J Biol Chem2023
36973268Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma.Nat Commun2023
37198186Author Correction: Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma.Nat Commun2023
36470426Mapping the KRAS proteoform landscape in colorectal cancer identifies truncated KRAS4B that decreases MAPK signaling.J Biol Chem2023
36973268Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma.Nat Commun2023
37198186Author Correction: Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma.Nat Commun2023
35001477Glycemic outcomes of children 2-6â¿¿years of age with type 1 diabetes during the pediatric MiniMedâ¿¢ 670G system trial.Pediatr Diabetes2022
36150054Rising Hemoglobin A1c in the Nondiabetic Range Predicts Progression of Type 1 Diabetes As Well As Oral Glucose Tolerance Tests.Diabetes Care2022
35998266The Transition From a Compensatory Increase to a Decrease in C-peptide During the Progression to Type 1 Diabetes and Its Relation to Risk.Diabetes Care2022
35001477Glycemic outcomes of children 2-6â¿¿years of age with type 1 diabetes during the pediatric MiniMedâ¿¢ 670G system trial.Pediatr Diabetes2022
36150054Rising Hemoglobin A1c in the Nondiabetic Range Predicts Progression of Type 1 Diabetes As Well As Oral Glucose Tolerance Tests.Diabetes Care2022
35998266The Transition From a Compensatory Increase to a Decrease in C-peptide During the Progression to Type 1 Diabetes and Its Relation to Risk.Diabetes Care2022
33417831Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma.Cancer Cell2021
33798439The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment.Cell2021
33900843School Nurse Perspectives on Do-It-Yourself Automated Pancreas Systems in the School Setting.Diabetes Technol Ther2021
33577785Proteogenomic and metabolomic characterization of human glioblastoma.Cancer Cell2021
34036290A community effort to identify and correct mislabeled samples in proteogenomic studies.Patterns (N Y)2021
33417831Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma.Cancer Cell2021
33431422The Evolution of Hemoglobin A<sub>1c</sub> Targets for Youth With Type 1 Diabetes: Rationale and Supporting Evidence.Diabetes Care2021
34747368IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes.JCI Insight2021
34858420Targeted Mass Spectrometry Enables Multiplexed Quantification of Immunomodulatory Proteins in Clinical Biospecimens.Front Immunol2021
34671754Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling.Cell Rep Methods2021
34842409Rationally Designed Topological Quantum Dots in Bottom-Up Graphene Nanoribbons.ACS Nano2021
34359745Targeted Mass Spectrometry Enables Quantification of Novel Pharmacodynamic Biomarkers of ATM Kinase Inhibition.Cancers (Basel)2021
33900843School Nurse Perspectives on Do-It-Yourself Automated Pancreas Systems in the School Setting.Diabetes Technol Ther2021
33798439The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment.Cell2021
33577785Proteogenomic and metabolomic characterization of human glioblastoma.Cancer Cell2021
34858420Targeted Mass Spectrometry Enables Multiplexed Quantification of Immunomodulatory Proteins in Clinical Biospecimens.Front Immunol2021
34671754Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling.Cell Rep Methods2021
34842409Rationally Designed Topological Quantum Dots in Bottom-Up Graphene Nanoribbons.ACS Nano2021
34747368IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes.JCI Insight2021
34036290A community effort to identify and correct mislabeled samples in proteogenomic studies.Patterns (N Y)2021
34359745Targeted Mass Spectrometry Enables Quantification of Novel Pharmacodynamic Biomarkers of ATM Kinase Inhibition.Cancers (Basel)2021
33431422The Evolution of Hemoglobin A<sub>1c</sub> Targets for Youth With Type 1 Diabetes: Rationale and Supporting Evidence.Diabetes Care2021
32125891Precision Dosing of Rapid-Acting Insulin Matters.Diabetes Technol Ther2020
32132004Erratum. Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention. Diabetes Care 2019;42:2228-2236.Diabetes Care2020
32125891Precision Dosing of Rapid-Acting Insulin Matters.Diabetes Technol Ther2020
31923397Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma.Cell2020
32649875Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression.Cell2020
32529193Proteogenomic Characterization of Ovarian HGSC Implicates Mitotic Kinases, Replication Stress in Observed Chromosomal Instability.Cell Rep Med2020
33067450A high-stringency blueprint of the human proteome.Nat Commun2020
32954372Correction: Proteogenomic Characterization of Ovarian HGSC Implicates Mitotic Kinases, Replication Stress in Observed Chromosomal Instability.Cell Rep Med2020
31923397Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma.Cell2020
33067450A high-stringency blueprint of the human proteome.Nat Commun2020
32649875Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression.Cell2020
32954372Correction: Proteogenomic Characterization of Ovarian HGSC Implicates Mitotic Kinases, Replication Stress in Observed Chromosomal Instability.Cell Rep Med2020
32529193Proteogenomic Characterization of Ovarian HGSC Implicates Mitotic Kinases, Replication Stress in Observed Chromosomal Instability.Cell Rep Med2020
32132004Erratum. Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention. Diabetes Care 2019;42:2228-2236.Diabetes Care2020
30645970Proteogenomic Characterization of Human Early-Onset Gastric Cancer.Cancer Cell2019
31585088Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma.Cell2019
  • 1 - 50 of 374

Recommended Authors

Cheryl F Lichti
Washington University School of Medicine
Career Start Year 2005
Number of shared co-authors 26
Brian L Hood
The Henry M. Jackson Foundation for the Advancement of Military Medicine
Career Start Year 2004
Number of shared co-authors 6
Vineet Sangar
Institute for Systems Biology
Career Start Year 2003
Number of shared co-authors 2
Ludovic Gillet
ETH Zurich
Career Start Year 2002
Number of shared co-authors 8
Andrey V Lisitsa
Institute of Biomedical Chemistry
Career Start Year 2001
Number of shared co-authors 22
Stella Somiari
Windber Research Institute
Career Start Year 2000
Number of shared co-authors 4
Shawn Levy
HudsonAlpha Institute for Biotechnology
Career Start Year 1999
Number of shared co-authors 7
Maria D Person
Center for Biomedical Research Support, The University of Texas at Austin
Career Start Year 1999
Number of shared co-authors 3
Thomas P Conrads
Women's Health Integrated Research Center, Inova Health System
Career Start Year 1998
Number of shared co-authors 22
??kos V??gv??ri
Karolinska Institutet
Career Start Year 1998
Number of shared co-authors 22
David A Sarracino
Harvard Partners Center For Genetics and Genomics
Career Start Year 1998
Number of shared co-authors 5
Janne Lehti??
Karolinska Institutet
Career Start Year 1997
Number of shared co-authors 9
Wenzhong Xiao
Stanford University
Career Start Year 1997
Number of shared co-authors 10
Michael R Shortreed
University of Wisconsin-Madison
Career Start Year 1996
Number of shared co-authors 19
Wim Van Criekinge
Ghent University
Career Start Year 1995
Number of shared co-authors 1
Sudhir Varma
Center for Cancer Research, National Cancer Institute
Career Start Year 1994
Number of shared co-authors 2
Jiri Adamec
University of Nebraska (UNL)
Career Start Year 1993
Number of shared co-authors 2
Keith A Baggerly
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 3
Gregory J Tsongalis
Dartmouth Health and the Dartmouth Cancer Center, USA Geisel School of Medicine
Career Start Year 1990
Number of shared co-authors 2
Andrea Urbani
National Research Council (CNR)
Career Start Year 1990
Number of shared co-authors 21
Jong-Il Kim
Genomic Medicine Institute, Medical Research Center, Seoul National University
Career Start Year 1989
Number of shared co-authors 2
Richard R Drake
Medical University of South Carolina
Career Start Year 1989
Number of shared co-authors 11
Emanuel F Petricoin
Center for Applied Proteomics and Molecular Medicine, George Mason University
Career Start Year 1988
Number of shared co-authors 31
Philip J R Day
University of Cape Town
Career Start Year 1988
Number of shared co-authors 2
Johan Lindberg
Karolinska Institute
Career Start Year 1988
Number of shared co-authors 4
Eivind Hovig
Center for Bioinformatics, University of Oslo
Career Start Year 1987
Number of shared co-authors 2
Peter J Oefner
Institute of Functional Genomics, University of Regensburg
Career Start Year 1985
Number of shared co-authors 7
Stephen H Friend
University of Oxford
Career Start Year 1978
Number of shared co-authors 6
Samir M Hanash
University of Texas MD Anderson Cancer Center
Career Start Year 1977
Number of shared co-authors 43
William E Grizzle
University of Alabama at Birmingham
Career Start Year 1974
Number of shared co-authors 4

Collaborators

Christopher R Kinsinger
Co-authored papers 43
Emily S Boja
Office of Cancer Clinical Proteomics Research, National Cancer Institute
Co-authored papers 41
Mehdi Mesri
Co-authored papers 32
Steven A Carr
Broad Institute of MIT and Harvard
Co-authored papers 27
Tara Hiltke
Office of Cancer Clinical Proteomics Research, National Cancer Institute
Co-authored papers 24
Daniel W Chan
Division of Clinical Chemistry, Johns Hopkins University
Co-authored papers 21
Amanda G Paulovich
Co-authored papers 19
Richard D Smith
Pacific Northwest National Laboratory
Co-authored papers 18
Daniel C Liebler
Co-authored papers 18
Matthew J Ellis
Co-authored papers 16
Bing Zhang
Baylor College of Medicine
Co-authored papers 16
Robert Rivers
Co-authored papers 15
Reid Townsend
Co-authored papers 15
Karin D Rodland
Oregon Health and Science University
Co-authored papers 14
Sherri R Davies
Co-authored papers 13
David L Tabb
Co-authored papers 13
David Feny??
Institute for Systems Genetics, NYU Grossman School of Medicine
Co-authored papers 13
Jeffrey R Whiteaker
Co-authored papers 13
Li Ding
McDonnell Genome Institute, Washington University School of Medicine
Co-authored papers 13
Tao Liu
Pacific Northwest National Laboratory
Co-authored papers 13
Deepak Mani
Co-authored papers 12
Pei Wang
Co-authored papers 12
Zhen Zhang
Co-authored papers 12
Hui Zhang
Co-authored papers 11
Lisa J Zimmerman
Co-authored papers 11
Kelly V Ruggles
Co-authored papers 11
Carla J Greenbaum
Center for Interventional Immunology, Benaroya Research Institute at Virginia Mason
Co-authored papers 10
Matthew A Wyczalkowski
Washington University in St Louis
Co-authored papers 10
Song Cao
Washington University in St Louis
Co-authored papers 10
Amir Rahbar
Co-authored papers 10
Release 1.2